Meeting
2019 ASCO Quality Care Symposium
Potential impact of clinical trial (CT) participation on survival of patients with metastatic non-small cell lung cancer (NSCLC).
Authors
Cristina Merkhofer
University of Washington, Seattle, WA
Cristina Merkhofer, Keith D. Eaton, Renato G. Martins, Scott David Ramsey, Bernardo H. L. Goulart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Access to Care
Citation
J Clin Oncol 37, 2019 (suppl 27; abstr 137)
DOI
10.1200/JCO.2019.37.27_suppl.137
Abstract #
137
Poster Bd #
L6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association of progression-free survival and overall response rate with overall survival in first-line randomized trials of immune checkpoint inhibitor–based regimens for metastatic non–small cell lung cancer (NSCLC): An FDA pooled analysis.
First Author: Bernardo Haddock Lobo Goulart
Poster
2022 ASCO Annual Meeting
Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival.
First Author: Sebastian Yves Friedrich Michels
Poster
2020 ASCO Virtual Scientific Program
An FDA analysis of the association of tumor growth rate and overall and progression-free survival in metastatic non-small cell lung cancer (NSCLC) patients.
First Author: Yutao Gong
Poster
2020 ASCO Virtual Scientific Program
Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy.
First Author: Lova Sun